Skip to main content

Health condition · Clinically reviewed

Burkitt lymphoma, urgent, aggressive - and often curable with modern regimens.

One of the fastest-growing human cancers - and one of the most curable when treated promptly in a specialist centre with intensive chemotherapy, rituximab and CNS prophylaxis.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a UK haemato-oncology clinician before publication.

  • 02

    Sourced from guidance

    Checked against BSH, NICE, ESMO and WHO 2022 classification, with sources listed at the end.

  • 03

    Current for 2026

    Reflects modern UK practice, including DA-EPOCH-R, intensified CNS prophylaxis and CAR-T for relapse.

Key facts

Burkitt lymphoma at a glance.

The essentials, in plain English - the three subtypes, the MYC biology and the modern UK approach to treatment.

  • What it is

    A highly aggressive mature B-cell non-Hodgkin lymphoma - one of the fastest-growing human tumours, with a doubling time measured in hours to days.

  • Three subtypes

    Endemic (equatorial Africa, jaw/facial, EBV-driven), sporadic (Western, often abdominal) and immunodeficiency-associated (HIV, post-transplant PTLD).

  • Molecular hallmark

    MYC translocation - t(8;14) IGH-MYC in around 80 percent of cases, with t(2;8) and t(8;22) variants. Ki-67 proliferation index close to 100 percent.

  • Classic histology

    The "starry-sky" pattern - sheets of medium-sized B cells punctuated by tingible-body macrophages clearing apoptotic debris.

  • Modern regimens

    DA-EPOCH-R for many adults and HIV-positive patients; CODOX-M/IVAC with rituximab or LMB paediatric protocols for high-risk disease.

  • Outlook

    With intensive protocols and specialist care, cure rates of 80 to 90 percent for limited-stage and 60 to 80 percent for advanced disease are achievable.

Why this guide matters

Speed matters. Care matters more.

Burkitt lymphoma grows in days, but with rapid recognition, tumour lysis prophylaxis and intensive combination therapy, the majority of patients are cured.

  • Recognise it early

    Any rapidly enlarging mass with B symptoms and a very high LDH is Burkitt until proven otherwise - same-day haematology referral is the standard.

  • Prevent tumour lysis

    Rasburicase, generous IV fluids and close monitoring stop the cell-death cascade that used to cause deaths before chemotherapy could take effect.

  • Treat with intent to cure

    Modern regimens like DA-EPOCH-R, CODOX-M/IVAC with rituximab and paediatric LMB protocols cure most patients, including many with HIV-associated disease.

How the diagnosis is made

From first suspicion to a clear plan.

The steps a UK haematology team will normally follow, in order, so you know what to expect and why every one of them matters.

  1. 01

    Recognising

    Urgent recognition

    A rapidly enlarging mass, B symptoms, very high LDH or spontaneous tumour lysis triggers same-day haematology referral.

  2. 02

    Recognising

    Excisional biopsy

    A whole node or generous tissue sample is preferred - core biopsies can be diagnostic when access is difficult.

  3. 03

    Recognising

    Histology and immunophenotype

    Starry-sky appearance with CD10, CD19, CD20 and BCL6 positive, BCL2 negative and Ki-67 near 100 percent.

  4. 04

    Confirming

    MYC FISH and cytogenetics

    Confirms t(8;14), t(2;8) or t(8;22). WHO 2022 also recognises a Burkitt-like lymphoma with 11q aberration variant.

  5. 05

    Confirming

    Baseline bloods and metabolics

    LDH, urate, phosphate, potassium, calcium, creatinine and urinalysis - the tumour lysis panel that guides prophylaxis.

  6. 06

    Preparing

    Staging imaging and marrow

    PET-CT, bone marrow biopsy and lumbar puncture with CSF cytology and flow cytometry to complete St Jude/Murphy staging.

  7. 07

    Preparing

    Viral and organ workup

    HIV, hepatitis B and C, echocardiogram or MUGA, and fertility discussion before intensive chemotherapy begins.

Typical timeline: from suspicion to first cycle of chemotherapy within days, not weeks.

Symptoms

What Burkitt lymphoma looks like.

A classic mix of a rapidly enlarging mass, systemic B symptoms and, at times, spontaneous tumour lysis - features that mean the clock is short.

  • Rapidly growing mass

    A lump that visibly enlarges over days - jaw or facial in endemic disease, abdominal in most Western cases.

  • Abdominal presentation

    Ileo-caecal, mesenteric, ovarian or renal masses causing pain, obstruction, bleeding or a palpable swelling.

  • Jaw and facial swelling

    The classic endemic presentation in African children - painless facial or mandibular tumour, often with loose teeth.

  • B symptoms

    Drenching night sweats, unexplained fevers and weight loss of more than 10 percent in six months.

  • Bone marrow and CNS involvement

    Cytopenias, bone pain, cranial nerve palsies, headache or altered consciousness signal marrow or CNS spread.

  • Spontaneous tumour lysis

    A metabolic emergency - hyperuricaemia, hyperphosphataemia, hyperkalaemia and acute kidney injury before treatment even starts.

  • Immunodeficiency clues

    Presentation in a patient with HIV, a solid-organ or stem-cell transplant, or long-term immunosuppression.

  • Red flag - acute deterioration

    Rising creatinine, oliguria, confusion or new neurology needs same-day admission to a specialist centre.

Treatment

How Burkitt lymphoma is treated in the UK.

Urgent hospitalisation, tumour lysis prophylaxis and intensive combination chemotherapy with rituximab and mandatory CNS prophylaxis - with CAR-T for relapse.

  • Tumour lysis prophylaxis

    Rasburicase, generous IV fluids, allopurinol where appropriate, and close biochemical monitoring before and during the first cycles.

  • DA-EPOCH-R

    Dose-adjusted etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin and rituximab - practice-changing in adults and HIV-positive disease.

  • CODOX-M / IVAC with rituximab

    An intensive alternating protocol used for high-risk adult disease in many UK centres, delivered in specialist units.

  • LMB paediatric regimens

    French Lymphome Malin B protocols - risk-stratified, intensive combination chemotherapy for children and adolescents.

  • CNS prophylaxis

    Mandatory - intrathecal methotrexate and cytarabine plus high-dose systemic methotrexate or cytarabine across the regimen.

  • Rituximab

    Anti-CD20 monoclonal antibody added to every modern Burkitt regimen - a substantial gain in survival across age groups.

  • Salvage and autologous SCT

    For relapsed or refractory disease - platinum-based salvage followed by high-dose therapy and autologous stem-cell transplant in fit patients.

  • CAR-T cell therapy

    Axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel are used for aggressive B-cell relapse, with newer constructs in Burkitt trials.

What this guide is based on

The sources behind every claim on this page.

UK national guidance, international consensus and specialist society standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your haematology team knows your case and history and can tell you which parts apply to you. If in doubt, get seen the same day.

  • WHO Classification of Haematolymphoid Tumours, 5th edition (2022).

  • British Society for Haematology (BSH). Guidelines on the management of Burkitt lymphoma.

  • NICE. Non-Hodgkin lymphoma: diagnosis and management (NG52).

  • ESMO. Burkitt lymphoma clinical practice guidelines.

  • NCI. Dose-adjusted EPOCH-R in Burkitt lymphoma (Dunleavy et al.).

  • Lymphoma Action UK. Patient information on Burkitt lymphoma.

Red flags

When Burkitt lymphoma is a same-day emergency.

Almost every new Burkitt presentation is urgent. These are the features that make it an even more time-critical emergency.

  • Spontaneous tumour lysis

    Metabolic derangement before treatment starts - a medical emergency needing rasburicase, fluids and renal support.

  • Airway compromise

    A rapidly growing head, neck or mediastinal mass with stridor, dysphagia or venous engorgement needs same-day airway assessment.

  • Bowel obstruction or perforation

    Abdominal Burkitt can present with acute obstruction or perforation - surgical and oncology review together.

  • CNS involvement

    New headache, cranial nerve palsy, meningism or confusion - urgent imaging and lumbar puncture with CSF cytology.

  • Very high LDH

    Values many times the upper limit of normal signal a large tumour burden and high tumour lysis risk.

  • Cytopenias with marrow disease

    Deep anaemia, thrombocytopenia or neutropenia at diagnosis needs urgent transfusion support and infection precautions.

  • HIV or transplant patient

    Immunodeficiency-associated Burkitt needs joint haematology, infectious diseases and transplant team input from day one.

  • Pregnancy

    Rare but complex - specialist multidisciplinary care balances maternal treatment intensity with fetal outcome.

  • Suspected relapse

    New mass, rising LDH, fresh B symptoms or CSF findings after treatment - urgent re-biopsy and salvage planning.

Living with it

Intensive treatment, with real chances of cure.

Four things that make the biggest difference through and after treatment - the right centre, an early fertility conversation, specialist support and a plan for life afterwards.

A quiet reminder

You are not doing this alone.

A clinical nurse specialist, a haematology team and UK charities like Lymphoma Action, Blood Cancer UK and Macmillan are there for you and your family from diagnosis onwards.

  1. 01 Team

    Treated in a specialist centre

    Care is led by a haemato-oncology multidisciplinary team - a UK specialist unit is the right place for intensive protocols and CAR-T.

  2. 02 Fertility

    Talk about fertility early

    Sperm banking, oocyte or embryo freezing and ovarian tissue preservation should be discussed before chemotherapy - time is short but options exist.

  3. 03 Support

    Clinical nurse specialist and charities

    A specialist nurse coordinates practical support. Lymphoma Action UK, Blood Cancer UK and Macmillan offer information, helplines and peer support.

  4. 04 Recovery

    Life after treatment

    Follow-up covers late effects, cardiac and fertility health, second cancers and psychological recovery - most people who are cured stay cured.

Frequently asked

Everything we get asked about Burkitt lymphoma.

Quick answers on subtypes, MYC biology, tumour lysis, modern regimens and outlook.

  • What is Burkitt lymphoma?

    Burkitt lymphoma is a highly aggressive mature B-cell non-Hodgkin lymphoma driven by a MYC gene translocation. It is one of the fastest-growing human cancers, with a tumour doubling time measured in hours to days, but it is also one of the most curable when treated promptly in a specialist centre.

  • What are the three subtypes?

    The endemic form affects children in equatorial Africa and Papua New Guinea, is strongly linked to Epstein-Barr virus and malaria, and typically presents as a jaw or facial mass. The sporadic form is the Western pattern - often abdominal disease in children and adults, EBV-associated in about 30 percent. The immunodeficiency-associated form arises in HIV, post-transplant lymphoproliferative disorder and other immunosuppressed patients.

  • How is Burkitt lymphoma diagnosed?

    Diagnosis needs tissue - ideally an excisional biopsy - showing sheets of medium-sized B cells with a starry-sky appearance and a Ki-67 index close to 100 percent. Immunophenotype is CD10, CD19, CD20 and BCL6 positive with BCL2 negative, and MYC FISH confirms t(8;14) or a variant translocation. Staging uses PET-CT, bone marrow biopsy and lumbar puncture under the St Jude/Murphy system.

  • What is tumour lysis syndrome and why does it matter?

    Because Burkitt cells grow and die so quickly, they can release large amounts of potassium, phosphate and urate into the blood - sometimes before treatment even begins. This can cause acute kidney injury, cardiac arrhythmia and death. UK protocols use rasburicase, generous intravenous fluids, allopurinol where appropriate and close biochemical monitoring to prevent and treat it.

  • What are the modern treatment options?

    The mainstays are intensive combination chemotherapy with rituximab and mandatory CNS prophylaxis. DA-EPOCH-R is widely used in adults and HIV-positive patients following the NCI trial. CODOX-M/IVAC with rituximab is an alternative for higher-risk adult disease, and paediatric LMB protocols are used in children and adolescents. Relapsed disease is treated with salvage chemotherapy, autologous stem-cell transplant and CAR-T cell therapy in selected patients.

  • What is the outlook after treatment?

    Modern regimens cure 80 to 90 percent of patients with limited-stage disease and 60 to 80 percent of those with advanced disease, including many with HIV-associated Burkitt. Relapse tends to happen early - most within the first year - and long survival beyond two years usually means cure. Follow-up focuses on late effects, fertility, cardiac health and psychological recovery.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.